中文

Journal Publications

[1]Lei-Yun Wang, Ji-Ye Yin, Jia-Jia Cui, Ao-Xiang Guo.Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.[J]. New Zealand.OncoTargets and therapy, 2018, 11 (1) : 529-538.
[2]Lei-Yun Wang, Jia-Jia Cui, Ji-Ye Yin, Zhao-Qian Liu, Hong-Hao Zhou, Wei-Jing Gong, Tao Zhu.Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients[J]. England.Scientific reports, 2017, 7 (1) : 5082.
[3]Ao-Xiang Guo, Fan Xiao, Wei-Hua Shao, Yan Zhan, Le Zhang, Jing Xiong, Yang Gao, Ji-Ye Yin.Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC[J].OncoTargets and Therapy, 2020, 13: 6485-6496.
[4]Ao-Xiang Guo, Jia-Jia Cui, Lei-Yun Wang, Ji-Ye Yin.The role of CSDE1 in translational reprogramming and human diseases[J].Cell Communication and Signaling, 2020, 18 (14)
[5]Qi Xiao, Jiye yin, Zhaoqian Liu, Wei Zhang, Xiaoyuan Mao, Xi Li, Lulu Yu, Bing Yu, Hanxue Huang, Ying Gao, Chenxue Mao.Establishing a Prediction Model for the Efficacy of Platinum—Based Chemotherapy in NSCLC Based on a Two Cohorts GWAS Study. Switzerland.Journal of Clinical Medicine, 2023, 12 (4) : 1318.
[6]Lu-Lu Yu, Cheng-Xian Guo, Jin-Gao Li, Xiao-Xue Xie, Ji-Ye Yin, Bi-Wen Hu, Han-Xue Huang, Bing Yu, Qi Xiao, Qiao-Li Lv, Chen-Hui Luo.A two-stage genome-wide association study identifies novel germline genetic variations in CACNA2D3 associated with radiotherapy response in nasopharyngeal carcinoma.Journal of Translational Medicine, 2023, 21 (1) : 11.
[7]Wang Y, Guo CX, Li JG, Yin JY, Xiao F, Zhao Y, Mao CX, Yu LL, Wang LY, Xiao Q, Liu R, Li X, McLeod HL, Hu BW, Huang YL, Lv QL, Xie XX, Huang WH, Zhang W.A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma..MOLECULAR CANCER, 2022, 21 (1) : 169.
[8]Ke Liu, Yan Zhan, Jia‑Jia Cui, Qian‑Ying Ouyang, Xiang‑Ping Li, Ji‑Ye Yin, Dong‑Hua Yang, Qi‑Si Lu.Reprogramming the tumor microenvironment by genome editing for precision cancer therapy[J]. England.Molecular Cancer, 2022, 21 (1) : 98.
[9]Liu K*, Wu W#, Yin JY#, OuYang QY, Zhan Y, Yin H, Liu BX, Tan LM, Liu R.Pharmacoepitranscriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment[J].Molecular Therapy Nucleic Acids, 2022, 28: 464-476.
[10]Chen-Xue Mao, Juan Chen, Ji-Ye Yin, Zhao-Qian Liu, Ting Zou, Yuan-Kang Zhou, Jun-Yan Liu, Xi Li, Xiang-Ping Li, Min Li, Pin-Hua Pan, Wei Zhuo, Yang Gao, Shuo Hu, De-Sheng Xiao, Lin Wu, Zhan Wang, Heng Xu, Wen Yang, Ying-Jie Xu, Hai-Hua Xiao, Kazuhiko Hanada, Wei Zhang, Hong-Hao Zhou.Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer.Acta Pharmaceutica Sinica B, 2022, 12 (3) : 1514-1522.
[11]Yan Zhan, Hui Yin, Ji-Ye Yin, B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies[J]. Australia.Int J Biol Sci, 2022, 18 (5) : 1844-1851.
[12]Yi-Xin Chen, Ji-Ye Yin, Zhao-Qian Liu, Chen-Jing Wang, De-Sheng Xiao, Bai-Mei He, Min Li, Xiao-Ping Yi, Wei Zhang.eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer[J]. Netherlands.Pharmacological research, 2021, 174: 105934.
[13]Lei-Yun Wang, Jia-Jia Cui, Qian-Ying OuYang, Yan Zhan, Cheng-Xian Guo, Ji-Ye Yin, Yi-Min Wang, Xiang-Yang Xu, Lu-Lu Yu, Hui Yin, Yang Wang, Chen-Hui Luo.Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude[J]. England.EPMA J, 2021: 1-18.
[14]Juan Chen, Jun-Yan Liu, Zhao-Qian Liu, Jian-Ting Zhang, Ji-Ye Yin, Zi-Zheng Dong, Ting Zou, Zhan Wang, Yao Shen, Wei Zhuo, Xiang-Ping Li, Di Xiao, Hai-Tao Liu, Xiang Chen, Hong-HaoZhou.The effect of eIF3a on anthracycline-based chemotherapy resistance by regulating DSB DNA repair[J]. England.Biochemical pharmacology, 2021, 190: 114616.
[15]Yan Zhan, Ji-Ye Yin, Xiang-Ping Li, COVID-19 one year later: a retrospect of CRISPR-Cas system in combating COVID-19[J]. Australia.Int J Biol Sci, 2021, 17 (8) : 2080-2088.
[16]Wang LY, Yin JY, Guo CX, Zhan Y, Ouyang QY, Cui JJ.Remdesivir and COVID-19.Lancet, 2020, 396 (10256) : 953–954.
[17]Wang Lei-Yun, Yin Ji-Ye, Cui Jia-Jia, Guo Cheng-Xian.A New Way to Discover IRESs in Pathology or Stress Conditions? Harnessing Latest High-Throughput Technologies.[J]. United States.Bioessays, 2020, 42 (3) : 1-10.
[18]Jia-Jia Cui, Ji-Ye Yin, Xianquan Zhan, Hong-Hao Zhou, Zhi-Rong Tan, Lei-Yun Wang.Mass spectrometry-based personalized drug therapy[J].Mass Spectrometry Reviews, 2020, 39 (5-6) : 523-552.
[19]Wang Lei-Yun, Cui Jia-Jia, Liu Jun-Yan, Yin Ji-Ye, Guo Ao-Xiang, Zhao Zhen-Yu, Liu Ying-Zi, Wu Ji-Chu, Li Min, Hu Cheng-Ping, Gao Yang, Zhou Hong-Hao.Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer.[J]. England.Scientific data., 2018, 5 (1) : 1-8.
[20]Yin JY#, Guo AX, Cui JJ, Wang LY.Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients[J].Onco Targets Ther, 2018, 11: 529-538.

total49 1/3

firstpreviousnext last Page

Jiye Yin

Zip Code:
Postal Address:
Email:

Central South University All rights reserved 湘ICP备05005659号-1

Click:

The Last Update Time:..